Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Applied Therapeutics Inc (Applied Therapeutics) is a biopharmaceutical company that develops novel drug candidates against validated molecular targets in rare diseases. The company lead pipeline products include govorestat (AT-007) for the treatment of galactosemia, SORD deficiency and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG). Applied Therapeutics other pipeline products include AT-001 for diabetic cardiomyopathy and AT-003 for diabetic retinopathy. The company develops aldose reductase inhibitor for the treatment of central nervous system (CNS) rare metabolic diseases. Applied Therapeutics is headquartered in New York City, New York, the US.
Headquarters
United States of America
Address
Suite 1400, 545 Fifth Avenue, New York City, 10017
Website
www.appliedtherapeutics.com
Telephone
1 212 2209226
No of Employees
28
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$455,000
Applied Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| AT-007 (Govorestat): |
| Galactosemia |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In March, the company received an extension from the U.S. Food and Drug Administration for the New Drug Application for govorestat (AT-007) for the treatment of Classic Galactosemia. |
| 2024 | Others | In January, the company submitted a new drug application for govorestat to the U.S. Food and Drug Administration. |
| 2023 | Contracts/Agreements | In January, the company announced a partnership with Advanz Pharma for commercialization of AT-007 (govorestat) in Europe. |
Competitor Comparison
| Key Parameters | Applied Therapeutics Inc | Vertex Pharmaceuticals Inc | BioMarin Pharmaceutical Inc | Sarepta Therapeutics Inc | Amicus Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | New York City | Boston | San Rafael | Cambridge | Princeton |
| State/Province | New York | Massachusetts | California | Massachusetts | New Jersey |
| No. of Employees | 28 | 6,400 | 3,221 | 835 | 511 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John Johnson | Chairman | Executive Board | 2020 | - |
| Les Funtleyder | Director; Chief Financial Officer; Chief Executive Officer - Interim | Executive Board | 2023 | 55 |
| Constantine Chinoporos | Chief Operating Officer; Chief Business Officer | Senior Management | 2023 | 59 |
| Evan Bailey, MD | Chief Medical Officer | Senior Management | 2025 | - |
| Dale Hooks | Chief Commercial Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer